Business Wire

Forge Closes Over $150M in Funding, Adds New Investors Amid Another Record-Breaking Quarter

4.5.2021 17:30:00 EEST | Business Wire | Press release

Share

Forge Global, Inc. (“Forge”), the leading global private securities marketplace, announced today that it has received FINRA approval to operate as a single broker dealer with SharesPost, which Forge merged with in 2020, and that it closed an oversubscribed round of more than $150M in new funding. Total funding raised to date exceeds $250M with the latest round including existing investor Deutsche Börse and Forge’s new investors Temasek, Wells Fargo Strategic Capital, LUN Partners Group and others. The continued interest from global strategic and financial investors validates Forge’s leadership position as it continues to develop new, innovative products and services to meet the needs of the private market.

“We’re excited to have these incredible companies partner with Forge as we continue to build the operating system for the private market,” said Forge CEO Kelly Rodriques. “With their support and backing, and the momentum coming from the SharesPost merger, we are in an excellent position to continue to build world-class solutions and bring data, technology and liquidity at scale to the private markets.”

Since inception, Forge has completed more than $9B in transactions in nearly 400 private companies. In the months since its acquisition of SharesPost, the company tallied three consecutive record-breaking quarters including in Q1 2021 when Forge completed 1400 transactions totaling more than $730M of volume.

Forge intends to use the increased funding to continue to expand service offerings in the US and beyond. Jane Atherton, Managing Director, Investment at Temasek International and Paul Hilgers, Managing Director of Deutsche Börse's cash market business, will join Forge’s board.

“The importance of private markets is growing – for companies and investors alike,“ explains Christoph Hansmeyer, Head of Group Strategy & M&A at Deutsche Börse. “Investing in Forge pays testament to our commitment to help companies access liquidity both publicly and privately, and allows global investors to participate in the wealth created in both the public and private markets.”

With more than 642 private unicorn companies globally totaling $2T in collective valuation and with many of those staying private for 10 years or more, unicorn companies are increasingly turning to the private market for liquidity solutions that Forge provides. Global institutions, through their investments in Forge, are signaling increased interest in innovative new products and services that build on the core secondary trading capabilities that the Forge platform delivers.

"The private securities market plays an increasingly important role in today’s financial landscape, and Wells Fargo recognizes the significance of a digital platform like Forge in the ongoing evolution of this marketplace,” said Tom Richardson, Head of Principal Technology Investments at Wells Fargo Strategic Capital. “Forge's liquidity solutions simplify the complexities of private market transactions and introduces further transparency into the price discovery process. We’re excited about the opportunities this brings to our customers and look forward to seeing Forge’s continued growth.”

In February 2021, Forge launched Forge Company Solutions, a comprehensive liquidity solution suite for private, high-growth companies to facilitate custom liquidity programs including executive liquidity, company-sponsored employee liquidity, tender offers and direct listings.

About Forge

Forge serves the complex and emerging needs of the private market ecosystem by forging new connections through our technology, data and expertise. Founded in 2014, the firm empowers investors and shareholders by facilitating liquidity in the private markets. Forge is backed by top Silicon Valley investors and large, global institutions including Deutsche Börse, Temasek, Wells Fargo, BNP Paribas, FT Partners, Draper Associates, Peter Thiel, Munich Re Ventures and LUN Partners Group. . Securities related services are offered through Forge Market, LLC (“Forge Markets”) and SharesPost Financial Corporation (“SPFC”), each of which is a member of FINRA/SIPC and wholly owned subsidiaries of Forge Global, Inc. Transactional information includes trades conducted through SPFC, Forge Markets, and Emerson Equity, LLC (Member FINRA/SIPC and a broker dealer for SharesPost, Inc.) in 2011.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kelsey Quickstad
press@forgeglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye